Loading...
Concern about the virologic efficacy and cardiovascular safety of abacavir/3TC relative to tenofovir/FTC has led some clinicians to consider a regimen switch for their clinically stable patients. This strategy was recently evaluated in the SWIFT study — a prospective, randomized trial funded by the makers of tenofovir/FTC. Results were presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention [Campo R et al. Abstract WELBB03].
A total of 311 clinically stable patients with virologic suppression on abacavir/3TC + a boosted protease inhibitor were randomized to continue their abacavir/3TC or change to tenofovir/FTC. At week 48, 83% of the abacavir/3TC group versus 86% of the tenofovir/FTC group remained on assigned stud…